Want to see NMTC full AI Analyst Report?
Top Page
NeuroOne Medical Technologies
(NASDAQ:NMTC)
Select Model
Select Model
Rating:45Neutral
Price Target:
$2.00
▲(5.26% Upside)
Action:Reiterated
Date:08/18/26
The score is held down primarily by weak financial performance—deep operating losses and sizable, worsening cash burn—despite strong recent revenue growth and low leverage. Technicals also reflect a clear downtrend. The earnings call provided some support via reiterated guidance and operational milestones, but near-term liquidity pressure and execution/timing uncertainty keep the overall score below average.
Positive Factors
Product revenue growth and gross margin
Rapid OneRF adoption and positive product gross profit show commercial traction. Sustained procedure growth could expand the revenue base and provide operating leverage, although the company must maintain margins while scaling.
Negative Factors
Deep operating losses
Revenue growth has not yet translated into sustainable profitability because operating expenses substantially exceed gross profit. Continued losses could limit investment capacity and require additional financing before scale benefits emerge.
Read all positive and negative factors
Positive Factors
Negative Factors
Product revenue growth and gross margin
Rapid OneRF adoption and positive product gross profit show commercial traction. Sustained procedure growth could expand the revenue base and provide operating leverage, although the company must maintain margins while scaling.
Read all positive factors
NeuroOne Medical Technologies (NMTC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$17.12M
Dividend YieldN/A
Average Volume (3M)532.45K
Price to Earnings (P/E)―
Beta (1Y)1.32
Revenue Growth-1.67%
EPS Growth7.34%
CountryUS
Employees18
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding9,105,763
10 Day Avg. Volume702,340
30 Day Avg. Volume532,447
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)5.04
Price to Sales (P/S)2.95
P/FCF Ratio-12.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.27Price Target Upside282.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
NeuroOne Medical Technologies Business Overview & Revenue Model
Company Description
NeuroOne Medical Technologies Corporation functions as a specialized medical technology enterprise. Its core mission involves the invention and market deployment of sophisticated thin-film electrode systems. These systems are crafted for diverse n...
How the Company Makes Money
NeuroOne makes money primarily by selling medical devices to hospitals and healthcare providers and/or through distribution channels. Its core revenue stream is product revenue from its thin-film electrode/lead offerings (including sEEG-related pr...
NeuroOne Medical Technologies Financial Statement Overview
Summary
Income Statement
27
Negative
Balance Sheet
58
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.00M | 12.10M | 3.45M | 1.95M | 171.17K | 178.15K |
| Gross Profit | 5.57M | 8.14M | 1.08M | 456.52K | -70.79K | -97.75K |
| EBITDA | -6.91M | -3.01M | -11.84M | -11.66M | -9.88M | -9.80M |
| Net Income | -7.15M | -3.61M | -12.32M | -11.86M | -10.00M | -9.95M |
Balance Sheet | ||||||
| Total Assets | 6.19M | 10.79M | 5.37M | 8.10M | 12.82M | 7.94M |
| Cash, Cash Equivalents and Short-Term Investments | 2.05M | 6.57M | 1.46M | 5.32M | 11.14M | 6.90M |
| Total Debt | 73.32K | 266.81K | 260.16K | 184.40K | 202.90K | 315.67K |
| Total Liabilities | 2.42M | 3.71M | 4.55M | 1.85M | 3.22M | 1.38M |
| Stockholders Equity | 3.77M | 7.07M | 822.01K | 6.25M | 9.60M | 6.55M |
Cash Flow | ||||||
| Free Cash Flow | -7.16M | -2.92M | -11.13M | -13.27M | -7.79M | -8.67M |
| Operating Cash Flow | -7.05M | -2.84M | -11.01M | -12.89M | -7.52M | -8.60M |
| Investing Cash Flow | -109.54K | -81.74K | -120.20K | 2.65M | -3.24M | -67.08K |
| Financing Cash Flow | 1.17M | 8.33M | 7.27M | 7.40M | 12.02M | 11.53M |
NeuroOne Medical Technologies Technical Analysis
Neutral
1.90
Price Trends
2.49
Negative
3.43
Negative
3.99
Negative
Market Momentum
-0.19
Negative
44.76
Neutral
75.49
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NMTC, the sentiment is Neutral. The current price of 1.9 is above the 20-day moving average (MA) of 1.73, below the 50-day MA of 2.49, and below the 200-day MA of 3.99, indicating a neutral trend. The MACD of -0.19 indicates Negative momentum. The RSI at 44.76 is Neutral, neither overbought nor oversold. The STOCH value of 75.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NMTC.
NeuroOne Medical Technologies Risk Analysis
NeuroOne Medical Technologies disclosed 51 risk factors in its most recent earnings report. NeuroOne Medical Technologies reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NeuroOne Medical Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $47.74M | -3.09 | -34.09% | ― | -53.40% | -1719.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $92.41M | -6.03 | 524.69% | ― | 33.45% | 0.24% | |
45 Neutral | $17.12M | -2.06 | -98.33% | ― | -1.67% | 7.34% | |
39 Underperform | $345.16K | >-0.01 | -333.19% | ― | ― | 36.00% |
* Healthcare Sector Average
NMTC
NeuroOne Medical Technologies
1.88
-2.97
-61.21%
SRTS
Sensus Healthcare
3.00
-0.20
-6.25%
ECOR
Electrocore
10.27
5.30
106.64%
MODD
Modular Medical
3.03
-17.97
-85.57%
RBOT
Vicarious Surgical
0.04
-6.37
-99.34%
NeuroOne Medical Technologies Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
NeuroOne Expands At-The-Market Equity Offering Capacity
Positive
Jun 12, 2026
On December 21, 2022, NeuroOne Medical Technologies Corporation entered into a Capital on Demand Sales Agreement with JonesTrading Institutional Services, allowing the company to sell common stock from time to time through an at-the-market equity ...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
NeuroOne Restates Quarterly Results After Revenue Recognition Error
Negative
May 22, 2026
On May 22, 2026, NeuroOne Medical Technologies said it would amend and restate its financial statements for the quarter ended March 31, 2026, after discovering a revenue-recognition error tied to a customer order modification at quarter-end. The r...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.